Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

26.29 +0.30 (+1.15%)
Streaming Delayed Price Updated: 2:09 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 468,045
Open 25.99
Bid (Size) 26.29 (5)
Ask (Size) 26.31 (3)
Prev. Close 25.99
Today's Range 25.98 - 26.90
52wk Range 12.61 - 27.98
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity
PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors. 
Via Chartmill
Pacira (PCRX) Q2 Revenue Rises 1.7%
Via The Motley Fool

Performance

YTD
+43.4%
+43.4%
1 Month
+19.2%
+19.2%
3 Month
+1.8%
+1.8%
6 Month
+4.7%
+4.7%
1 Year
+81.6%
+81.6%

More News

Read More
Pacira BioSciences Inc (NASDAQ:PCRX) Reports Mixed Q2 2025 Earnings with EPS Beat but Revenue Miss
Via Chartmill
Pacira BioSciences Reports Second Quarter 2025 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Earnings Scheduled For August 5, 2025
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Preview: Pacira BioSciences's Earnings
Via Benzinga
Insights Ahead: Pacira BioSciences's Quarterly Earnings
Via Benzinga
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock Worth Considering
Via Chartmill
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
Lifshitz Law PLLC Announces Investigations of Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), ModivCare, Inc. (NASDAQ: MODV), and Integral Ad Science Holding Corp. (NASDAQ: IAS)
Via ACCESS Newswire
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
From Pacira BioSciences
Via GlobeNewswire
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Strong Fundamentals
Via Chartmill
Lifshitz Law PLLC Announces Investigations of DMC Global Inc. (NASDAQ: BOOM), Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), and ModivCare, Inc. (NASDAQ: MODV)
Via ACCESS Newswire
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
From Grabar Law Office
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Solid Fundamentals
Via Chartmill
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
Where Pacira BioSciences Stands With Analysts
Via Benzinga
Pacira BioSciences Reports First Quarter 2025 Financial Results
From Pacira BioSciences
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 26.29
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 08/27/25 02:09 PM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.17B
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.